Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01063231
Other study ID # MA-201
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 2009
Est. completion date October 2010

Study information

Verified date November 2010
Source Medtronic - MITG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluate accuracy of PCCE-2 in detecting patients with colonic polyps as compared to conventional colonoscopy.


Description:

Standard evaluation of subjects with suspected colon diseases includes endoscopic imaging by colonoscopy and radiology testing such as: air-contrast barium enema, abdominal/pelvic CT, or virtual colonoscopy.

The Given® Diagnostic System offers an alternative approach for endoscopic visualization of the colon. Advantages of the Given® Diagnostic System include the elimination of the need for conscious sedation, the minimally invasive, painless nature of the exam, and the ability to pursue normal daily activities immediately following the procedure . Furthermore, compared to standard colonoscopy, the Given® Diagnostic System may be more readily accepted by the subjects, thereby improving subjects' willingness to undergo a diagnostic evaluation of the colon and comply with colorectal cancer screening recommendations.

The PillCam™ SB capsule (formerly M2A® Capsule) that was cleared by the FDA- in August 2001 for small bowel evaluation has been ingested to date by more than 1,000,000 people worldwide and is well accepted by patients and physicians as well as the professional societies. However, adequate visualization of the colon cannot be achieved with the standard PillCam™ SB capsule because of the anatomical and physiological properties of the colon which are significantly different than the small bowel. Moreover, other issues that limit the evaluation of the colonic mucosa by the standard PillCam™ SB procedure include an unsatisfactory level of colon cleanliness and slow progression of the PillCam™ SB capsule through the colon during the desired examination time. Therefore, the development and introduction of a specially designed, customized colon capsule combined with a dedicated capsule colonoscopy procedure protocol will allow for more efficient evaluation of the colonic mucosa. This is expected to improve the capability of the Given® Diagnostic System to detect colonic pathologies and to serve as a diagnostic and screening tool for colonic disease. To date, several clinical studies have been conducted with Given® Diagnostic System and the PillCam™ Colon 1 capsule A pilot multicenter study is currently being conducted with a new Given® Diagnostic System and an advanced generation of the the PillCam™ Colon capsule - PillCam™ Colon 2. Capsule. The new development of Given® Diagnostic System and PillCam™ Colon 2 capsule is primarily aimed to increase sensitivity and specificity for polyp detection.

Further details of the Given® Diagnostic System and PillCam™ Colon 2 capsule can be found in the device description section.

This study is designed to evaluate the performance of the new version of Given® Diagnostic System and PillCam™ Colon 2 capsule in detecting patients with polyps and other colonic lesions as compared to conventional colonoscopy.


Recruitment information / eligibility

Status Completed
Enrollment 119
Est. completion date October 2010
Est. primary completion date September 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion criteria:

- Subject is between the ages of 18-80

- Subject was referred to colonoscopy for at least one of the following reasons:

- Colorectal cancer screening for age =50

- Clinical symptoms such as: rectal bleeding, hematochezia, melena, positive FOBT, recent change of bowel habits for age =50

- Positive findings in the colon (e.g. Polyp =10mm)

- Personal history of polyps that were removed at least 3 years ago (3 years and above)

Exclusion criteria

- Subject has dysphagia or any swallowing disorder

- Subject has congestive heart failure

- Subject has high risk of renal insufficiency associated with the use of sodium phosphate

- Subject is not eligible for colon preparation due to the presence of underlying conditions based on the clinical judgment of the investigator

- Subject has any allergy or other known contraindication to the medications used in the study

- Subject has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator

- Subject has a cardiac pacemaker or other implanted electro medical device.

- Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule.

- Subject with any condition believed to have an increased risk for capsule retention such as Crohn's disease, intestinal tumors, radiation enteritis, incomplete colonoscopies due to obstructions or NSAID enteropathy,

- Subject with gastrointestinal motility disorders

- Subject has known delayed gastric emptying

- Subject has any condition, which precludes compliance with study and/or device instructions.

- Women who are either pregnant at the time of screening, or are of child-bearing potential and do not practice medically acceptable methods of contraception.

- Subject suffers from life threatening conditions

- Subject currently participating in another clinical study

Study Design


Intervention

Device:
PillCam™ (Capsule Endoscopy) Colon 2 capsule
Medical Device

Locations

Country Name City State
Belgium Hospital Erasme - Gastro-Enterologie Brussels
France Chef de Service dHepato-Gastro-Enterologie et dAssistance Nutritionnelle CHU Nantes Nantes
France CHU Nancy Vandoeuvre Cedex
Germany Evangelisches Krankenhaus Dusseldorf
Italy Ospedale Gemelli,ENDOSCOPIA DIGESTIVA Roma
Netherlands Academic Medical Center University of Amsterdam Amsterdam
Spain Clinica Universitaria de Navarra Pamplona
Sweden Malmo University Hospital Malmo

Sponsors (1)

Lead Sponsor Collaborator
Medtronic - MITG

Countries where clinical trial is conducted

Belgium,  France,  Germany,  Italy,  Netherlands,  Spain,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Accuracy parameters of PillCam™ COLON 2 in detecting patients with colonic polyps =6mm and =10 mm as compared to conventional colonoscopy within 7 days
Secondary Diagnostic yield of PillCam™ COLON 2 in detecting colonic lesions as compared to conventional colonoscopy within 7 days
Secondary Assessment of colon cleansing level at different colon segments for PillCam and Colonoscopy within 7 days
Secondary Distribution of capsule excretion time up to 10 hours post ingestion based on Rapid videos within 7 days
Secondary Capsule transit time within stomach, small bowel and colon based on Rapid videos within 7 days
Secondary Prevalence of polyps at different size categories and locations as detected by capsule and by conventional colonoscopy Within 7 days
Secondary RAPID reading time Number, type and severity of adverse events with in 7 days
See also
  Status Clinical Trial Phase
Completed NCT02503696 - Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD) N/A
Terminated NCT01119027 - Assessing Effectiveness of Laparoscopic Colorectal Surgical Skills N/A
Completed NCT04074577 - Computer Aided Detection, Tandem Colonoscopy Study N/A
Not yet recruiting NCT04087824 - Deep Learning Algorithm for Recognition of Colonic Segments. N/A
Completed NCT03559543 - Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma Phase 2
Terminated NCT02503631 - Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers
Completed NCT01600209 - Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing N/A
Completed NCT01260168 - Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies N/A
Completed NCT00604162 - PillCam™ Colon Capsule Endoscopy (PCCE) in the Visualization of the Colon Phase 3
Recruiting NCT04598880 - Comparison of 1 Liter PEG With Ascorbate and Sodium Picosulfate / Magnesium Citrate for High Quality Colon Cleansing Phase 4
Completed NCT01738425 - A Clinical Phase I Study on GIC-1001 in Healthy Volunteers Phase 1
Completed NCT04080843 - Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients Phase 2
Terminated NCT04644315 - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Phase 2
Completed NCT02291445 - Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®), a Pharmacokinetic Study Phase 2
Completed NCT03037385 - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Phase 1/Phase 2
Completed NCT03139942 - Optical Polyp Testing for In Vivo Classification N/A
Completed NCT04263818 - Endoscopist and Endoscope Motions During Colonoscopy N/A
Recruiting NCT05923918 - A Study to Evaluate Safety and Efficacy of PBK_M2101 Phase 3
Completed NCT02647866 - Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis Phase 2
Completed NCT01397747 - Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer N/A